Parmax Pharma Complete Financial Statements
In FY2026, Parmax Pharma (PARMAX) reported revenue ₹12 Cr, net profit ₹-6 Cr and EPS ₹-11.12, with a net profit margin of -50.0%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse Parmax Pharma ownership structure to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
PARMAX Revenue, Net Profit & EBITDA — Year-on-Year Growth
PARMAX YoY (March 2025 vs March 2026) — revenue -57.1%, net profit -200.0%, expenses -42.9%. Also explore Parmax Pharma stock price data download to track price trends across different timeframes.
PARMAX Income Statement — Revenue, EBITDA & Net Profit
Parmax Pharma revenue ₹12 Cr, EBITDA ₹-4 Cr, net profit ₹-6 Cr, EPS ₹-11.12 (2026) — net profit margin -50.0%. For live price, earnings ratios and company overview, see Parmax Pharma screener.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 28 | 11 | 16 | 18 | 26 | 21 | 12 | 12 | 0 | 0 |
| Expenses | 16 | 28 | 14 | 13 | 16 | 23 | 19 | 11 | 11 | 0 | 0 |
| EBITDA | -4 | 0 | -3 | 2 | 3 | 4 | 2 | 1 | 1 | 0 | 0 |
| Operating Profit Margin % | -30.00% | 1.00% | -31.00% | 15.00% | 14.00% | 13.00% | 8.00% | 9.00% | 9.00% | 0.00% | 0.00% |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -6 | -2 | -6 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -6 | -2 | -6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | -11.12 | -5.60 | -34.56 | -0.28 | 0.38 | 2.02 | 1.15 | 0.21 | 0.00 | -0.02 | -0.01 |
PARMAX Balance Sheet — Assets, Liabilities & Shareholders' Equity
PARMAX total assets ₹28 Cr, total equity ₹-6 Cr, total liabilities ₹ Cr (2026).
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 28 | 19 | 15 | 18 | 18 | 23 | 21 | 20 | 17 | 8 | 5 |
| Current Assets | 17 | 10 | 6 | 8 | 7 | 10 | 9 | 9 | 9 | 4 | 2 |
| Fixed Assets | 8 | 8 | 9 | 10 | 10 | 11 | 10 | 5 | 6 | 3 | 3 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Investments | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 10 | 6 | 8 | 8 | 12 | 11 | 11 | 11 | 5 | 3 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 12 | 8 | 6 | 5 | 5 | 6 | 5 | 5 | 2 | 1 | 1 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | -6 | -2 | 0 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 |
| Share Capital | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | -11 | -6 | -4 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
PARMAX Cash Flow Statement — Operating, Investing & Financing
Parmax Pharma operating cash flow ₹-1 Cr, investing ₹-1 Cr, financing ₹1 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | 0 | 0 | 1 | 4 | 3 | 1 | 4 | -1 | 0 | 0 |
| Investing Activities | -1 | -2 | -1 | -2 | -3 | -2 | -3 | -4 | 0 | 0 | 0 |
| Financing Activities | 1 | 1 | 0 | -1 | 0 | 0 | 3 | 1 | 1 | 0 | 0 |
| Net Cash Flow | 0 | 0 | -1 | -2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |